Breaking AI & Tech News Analyzed

The Historic Lord's Milestone Morning everyone and welcome to the first Test of the English summer. Ashes, what Ashes? There's a lot to look forward to here. It's the 150th Test at Lord's, the first ground to reach that milestone. The next one looks like being Melbourne, some time in the 2040s, so here is one facet of cricket where England still rules the world. The Evolution of Bazball Strategy It's a reboot for our old friend Bazball, which is now going to be "slightly smarter" (according to Baz McCullum) or "a lot smarter" (according to Ben Stokes). As in Australia, these two seem to be singing from half of the same hymn sheet. New Faces and Last-Chance Opportunities It's a big moment for Emilio Gay, who will make his debut for England and open the batting in place of Zak Crawley, the only head to roll after a sobering winter. It may be an even bigger moment for Ollie Robinson, the prodigal seamer, as he walks into the last-chance saloon. New Zealand's Strong Challenge It's the biggest series for New Zealand since they last faced England in December 2024. They've played only six Tests since, but they've brought a strong squad, stuffed with seasoned batters and talented bowlers. Their last big series away from home went quite well: they beat India 3-0. Weather Threatens Cricket Action It's all set to be a great occasion. But have you seen the weather forecast? Bad for today, even worse for Saturday, bad again for Monday. If a bit of water could just be allowed to seep through the covers, it might be the only hope of a result. Toss and Match Preview The toss is at 10.30am (BST), at least in theory.

The Rise of Exam Cheating with Wearable Devices Cheating in exams could be magnified by the new generation of wearable hi-tech devices such as smartglasses or invisible earpieces, according to England’s qualifications watchdog. Ofqual's Concerns and Actions Ian Bauckham, the head of the Office of Qualifications and Examinations Regulation (Ofqual), revealed that GCSEs and A-level courses in England were being scrutinised over potential AI use in students’ coursework, after teachers said they were struggling to detect it. Ofqual recorded 2,225 cases of mobile phone and smart device cheating associated with GCSE, AS and A-levels last summer. The regulator is considering stronger checks to guard against students using AI in coursework. The Impact on Education Bauckham warned that recent increases in cheating enabled by smartphones may be made worse by the next wave of wearable devices, undermining England’s school qualifications system. “Our qualification system is a real national asset and we have to keep on top of this to stop this national asset being undermined, because that is not in anyone’s interests.” Future Measures Bauckham hinted that stronger checks were likely to be introduced, including: More frequent checks with students about their work before signing off on it. Increasing what is expected by way of referencing and sources. Potentially dropping coursework altogether.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

The Budget iPhone Gets a Premium UpgradeThe cheapest new iPhone has been upgraded for this year with a faster chip, double the storage, automatic portraits and MagSafe, providing even more of the core Apple smartphone experience for less. The iPhone 17e is an upgraded version of the mid-range "e" line launched last year and is the latest member of the iPhone 17 family, starting at £599 (€699/$599/A$999), undercutting the iPhone 17 and iPhone 16 by £200 and £100 respectively to be the cheapest new iPhone sold by Apple.Key Specifications and Design EvolutionThe new 17e maintains the same iPhone 14-like design with a large notch at the top of the screen and a 6.1in OLED screen. The aluminium sides feel great and the screen glass has been upgraded to the latest Ceramic Shield 2, which is tougher and includes an extremely effective anti-glare treatment that makes it a lot easier to see outdoors. The device also features MagSafe built into the back for magnetic accessories, such as Popsockets, wallets and chargers, which have been a key part of the iPhone experience since 2020.Screen: 6.1in Super Retina XDR (OLED) (460ppi)Processor: Apple A19 (4-core GPU)RAM: 8GBStorage: 256 or 512GBOperating system: iOS 26Camera: 48MP rear; 12MP front-facingConnectivity: 5G, wifi 6, NFC, Bluetooth 5.3, USB-C, Satellite and GNSSWater resistance: IP68 (6 metres for 30 mins)Dimensions: 146.7 x 71.5 x 7.8mmWeight: 170gPerformance and Battery Life AnalysisThe 17e features the A19 chip from the regular iPhone 17 but with one less GPU core, which reduces graphics performance slightly. Despite this, the phone remains very fast and capable of handling top-spec games. It also includes a decent 256GB of storage as standard, which should be sufficient space for most users with additional cloud backup options. The battery life is impressive, lasting approximately 52 hours between charges with general usage across 5G and wifi, meaning most users will need to charge it every other night.Market Positioning and Sustainability ImpactThe iPhone 17e lacks a few of the more advanced hardware features common to Apple's other phones, including wifi 7, Thread and Ultra Wideband (UWB). However, it maintains Apple's commitment to sustainability with more than 30% recycled material including aluminium, cobalt, copper, glass, gold, lithium, plastic, rare earth elements, steel, tin and tungsten. The battery should last in excess of 1,000 full-charge cycles with at least 80% of its original capacity, and can be replaced for £95. Out-of-warranty screen repairs cost £225, and the device was awarded seven out of ten for repairability by iFixit.Future Outlook for Apple's Budget LineupThe iPhone 17e represents Apple's continued strategy of making its ecosystem more accessible while maintaining premium quality standards. With this significant upgrade to the "e" line, Apple is likely to further solidify its position in the mid-range smartphone market, potentially attracting new users who might have previously considered Android alternatives. The inclusion of MagSafe and improved camera capabilities suggests Apple is gradually bringing more premium features to its more affordable models, potentially narrowing the gap between its budget and flagship offerings in future iterations.

The Enduring Appeal of Pocket-Sized PowerSamsung continues to champion the compact smartphone market with the release of the Galaxy S26. As competitors increasingly shift towards massive form factors, the S26 stands out as one of the best smaller handsets available, offering premium performance without the unwieldy footprint. While the overall design language remains familiar, the underlying hardware and software refinements ensure it remains highly competitive in a crowded market.Refined Dimensions and Exynos 2600 IntegrationThe physical design of the S26 features flat aluminium sides and a frosted glass back, weighing a remarkably light 167g. The display has been marginally expanded to 6.3 inches, but ultra-thin bezels ensure the physical footprint remains nearly identical to its predecessor. Under the hood, Samsung deploys its proprietary Exynos 2600 processor for global markets outside North America. Crucially, this chip nearly matches the performance and efficiency of Qualcomm's Snapdragon alternatives, ensuring snappy operation and solid battery life.Processor: Exynos 2600 (Global) / Snapdragon 8 Elite Gen 5 (North America)Battery Life: Approximately 40 hours on average use; 25W wired charging reaching 60% in 30 minutes.Camera System: 50MP main, 12MP ultrawide, and 10MP telephoto with 3x optical zoom.Pricing Strategy and Storage UpgradesLike many tech products relying heavily on memory chips, the Galaxy S26 has seen a notable price increase. The device now retails at £879 (or local equivalent), marking an £80 jump from the previous generation. However, Samsung mitigates this sticker shock by doubling the base storage to 256GB. This strategic pivot provides better long-term value for consumers, effectively offsetting the higher entry price with double the capacity for apps, media, and AI-driven processes.The AI-Driven Software EcosystemRunning on One UI 8.5 based on Android 16, the S26 is deeply integrated with Samsung's latest AI tools. Features like text and image editing, spam-blocking call assist, and the proactive Now Nudge assistant elevate the user experience by automating routine tasks. Samsung's commitment to software longevity is highly aggressive, with guaranteed updates extending to 28 February 2033. This extended lifecycle outpaces many rivals and makes the S26 a secure investment for the future.The Future of Compact AndroidsAs the smartphone market bifurcates between massive ultra-premium slabs and complex foldables, the standard compact flagship is becoming an endangered species. The Galaxy S26 proves that there is still substantial demand for highly capable, easily pocketable phones. Moving forward, Samsung's ability to pack top-tier silicon and advanced AI capabilities into a small frame will likely dictate the survival of this form factor, ensuring that users who prioritize one-handed usability are not left behind.

The Unlikely Motivation At 56, I am running my first marathon, an old, fat, bald dad surrounded by millennials in body-hugging Lycra and smiles that look AI-generated. But I am ahead of them. For they are only competing for positions and personal bests, and I am being chased by zombies. The Power of Zombies, Run! I started off accompanied by audiobooks, but when Ben Elton’s autobiography got a bit whiny, I remembered Zombies, Run! – an interactive running game for smartphones that came out years ago. That became my running companion. How the Game Works You start in the ruins of a shot-down chopper, with the voice in your ears trying to guide you to safety through the ranks of the undead. The interaction comes via short sections where you are told to run fast rather than lope. Overcoming Challenges Unfortunately, I spent the 90s playing football on hangovers and Red Bull without stretching once. My glutes and hamstrings give me constant pain after 10km, and the story is no longer enough to distract me. The Impact of Music Luckily, the best bit about Zombies, Run! is that you can link the game to a playlist on your phone, so you get a minute of narrative, then the music fades up for a bit before returning to the story. The Marathon Experience With Zombies on my back and banging tunes in the 170bpm range in my ears, I tore away, breaking my PB for 1km, 5km, 10km and half marathon as my band of apocalypse surviving chums and I investigated a weird ship and rescued a bunch of kids from an undead-strewn playground. The Unexpected Twist And then, at 15 out of 26 miles … my phone died. Suddenly, there was no distracting zombie story and no inspirational music. The Conclusion I got round. Eventually. But it was not Sonic the Hedgehog. It was more like Death Stranding, with your character carrying all of Swindon on his back.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Nothing Phone 4a Pro: A Departure from Glass-Clad Designs Nothing's latest smartphone, the Phone 4a Pro, marks a significant departure from its previous glass-clad designs. The new device features a solid aluminium body, a rare sight in the world of Android phones, and a large 6.83in OLED screen on the front. Design and Display The Phone 4a Pro has a slim aluminium body that feels great in hand, but its large size makes it a two-handed affair most of the time. The device features a high 144Hz refresh rate screen that keeps scrolling smooth, making it great for watching video on the commute. Camera and Battery Life The Phone 4a Pro has a large camera island on the back containing a big, bright circular dot-matrix LED screen, which can display notification icons, the time, timers, volume, and charge levels. The device is powered by a Qualcomm Snapdragon 7 Gen 4 chip and has a solid battery life that lasts two-plus days between charges. Specifications Screen: 6.83in 144Hz QHD+ OLED (450ppi) Processor: Qualcomm Snapdragon 7 Gen 4 RAM: 8 or 12GB Storage: 128 or 256GB Operating system: Nothing OS 4.1 (Android 16) Camera: 50MP main, 50MP 3.5x tele and 8MP ultrawide, 32MP selfie Verdict The Nothing Phone 4a Pro is a quirky smartphone that offers a unique design, solid performance, and good battery life. While it may not be the most powerful device on the market, it's a great option for those looking for a device that stands out from the crowd.

The Lead: Stokes' Defense of Archer's IPL Commitment Ben Stokes has defended England's decision to excuse Jofra Archer from the start of the Test summer so he could compete in the Indian Premier League, saying a more militant approach risks a situation where "players like him might not play for England again." While Stokes admitted he "totally understands people's frustrations around the situation," particularly given that Archer is tied to an ECB central contract which runs until 2027, he suggested its most high-profile critics were stuck in the past. The Modern Cricket Landscape: Player Opportunities and Expectations "There's another side to it, and a lot of it's got to do with the landscape of cricket and where it is at the moment," England's Test captain said. "I think a lot of the points that people have been making around Jof and that situation are to do with the landscape when they were playing. But it's completely different now. There's opportunities for cricketers now that there wasn't 10, 15, 20 years ago. "Yes, in an ideal situation it would be unbelievably great to have everyone you want available at every single opportunity. That is not the way of cricket at the moment. There is so much more out there for players. There are other opportunities and you want players to be able to do them, and also to play for England. The Archer Situation: IPL Success and Test Uncertainty Archer has just completed his most successful IPL season, taking 25 wickets for Rajasthan Royals as they reached the playoffs, putting him third in this year's bowling rankings. He played his last game on Friday, before flying to Barbados for what Brendon McCullum, the England coach, described as "a little bit of a break". He is expected to play some part in the Test series against New Zealand but will not be at Lord's when the first Test starts on Thursday, and it is not yet known whether he will be available for the second game, which begins at the Oval on 17 June. Criticism and Counterarguments: Former Players vs. Current Leadership "It's ludicrous, absolutely ludicrous," Doull told Sky. "How are you paying this guy up to £1m a year and he's not available for your first Test match? There's no reason that Jofra Archer couldn't have been bowling six or seven overs [with the red ball] in between [games]. The fact that he is not doing that tells me he has no interest in playing Test cricket. And why are the ECB not then having discussions with the [Royals] team, saying: 'We need him to be ready for Test match cricket'? I think it's completely wrong." But while Stokes acknowledged the criticism, he maintained his position: "There is a situation where it could get messy, and players like Jofra might not play for England again if you handle it in a different way, and that is not good for anyone. Jofra has shown that he's committed and loves playing for England. Just because he's not available for this first Test match does not change that." England's Performance Issues: Need for a Smarter Approach Stokes admitted that his team had developed a habit of "consistently letting ourselves down" at crunch moments in Test matches, a trend which their much-trailed reset is intended to address. "It's not a massive change, to be honest," he said. "As much as people want to hear us say that, it's not. It's being a lot smarter in those big moments in games, because I will admit that consistently when [they] were in the balance, when it was neither one way nor the other, we let ourselves down. The decisions we thought were the right ones to make let the opposition get ahead of us. Especially over the past 18 months, we've contributed towards losing games of cricket on too much of a consistent basis."